ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$8.71
0.16 (1.87%)
▲
5d:
+1.28%
30d:
+15.36%
90d:
+37.17%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACET shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ACET shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $8.71, which is considered slightly high relative to its 30-day fair value range of $7.67 to $8.82.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $8.34, while resistance sits at $9.42.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+307.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $8.34, while resistance sits at $9.42.
Market Sentiment: ACET has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $34.83 (+307.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.67 -
$8.82
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 307.4% below Wall St target ($34.83)
Trading Range Analysis
30-Day Trading Range
$7.67 -
$8.82
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.67
(19.2%)
Support & Resistance Levels
Support Level
$8.34
Resistance Level
$9.42
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.04
Wall Street Target
$34.83
(+307.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 14, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
74751 shares
2026-02-20
Ra Capital Management, L…
BUY
74268 shares
2026-02-19
Ra Capital Management, L…
BUY
74577 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
